Direxion Daily LLY Bear 1X ETF
ELIS
NASDAQ Global Select- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 1301 Avenue of the Americas, 28th Floor New York NY United States of America 10019
- IPO Date
- Mar 26, 2025
- Website
- direxion.com
- Similar Companies
- Business
- Direxion Daily LLY Bear 1X Shares (ELIS) is an exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 100% of the inverse (or opposite) of the daily performance of the common shares of Eli Lilly and Company (NYSE: LLY). The fund provides short exposure to LLY through financial instruments including swap agreements, options, and other derivatives that, in combination, deliver 1X daily inverse performance; it invests at least 80% of its net assets in such instruments and is designed for short-term trading by experienced investors who understand leverage and inverse risks. Issued by Direxion Shares ETF Trust and managed by Rafferty Asset Management, LLC, the fund features a gross expense ratio of 0.99% (net 0.97% through waivers expiring September 1, 2026) and trades on Nasdaq. Direxion, founded in 1997 and headquartered at 1301 Avenue of the Americas in New York, NY, specializes in leveraged and inverse ETFs, including single-stock products for tactical trading across sectors like pharmaceuticals and technology; the firm manages approximately $50.6 billion in assets as of June 30, 2025, with operations in the U.S. and Hong Kong. ELIS launched on March 26, 2025, as part of Direxion's expansion of its single-stock leveraged and inverse ETF lineup, alongside the complementary Direxion Daily LLY Bull 2X Shares (ELIL), Direxion Daily PANW Bull 2X Shares (PALU), and Direxion Daily PANW Bear 1X Shares (PALD) for exposure to Eli Lilly and Palo Alto Networks. This strategic launch extends Direxion's leadership in high-conviction, short-term trading tools amid volatility in healthcare and cybersecurity sectors, with no reported acquisitions, partnerships, or other major changes since inception.